<SEC-DOCUMENT>0001771910-20-000013.txt : 20200921
<SEC-HEADER>0001771910-20-000013.hdr.sgml : 20200921
<ACCEPTANCE-DATETIME>20200921160926
ACCESSION NUMBER:		0001771910-20-000013
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20200921
FILED AS OF DATE:		20200921
DATE AS OF CHANGE:		20200921

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ADC Therapeutics SA
		CENTRAL INDEX KEY:			0001771910
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			V8
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39071
		FILM NUMBER:		201186423

	BUSINESS ADDRESS:	
		STREET 1:		BIOPOLE
		STREET 2:		ROUTE DE LA CORNICHE 3B
		CITY:			EPALINGES
		STATE:			V8
		ZIP:			1066
		BUSINESS PHONE:		41 21 653 02 00

	MAIL ADDRESS:	
		STREET 1:		BIOPOLE
		STREET 2:		ROUTE DE LA CORNICHE 3B
		CITY:			EPALINGES
		STATE:			V8
		ZIP:			1066
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>dp137015_6k.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 3.5pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 16pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 6-K<BR>
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.85pt; text-align: center; text-indent: -6.85pt"><B>REPORT
OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.85pt; text-align: center; text-indent: -6.85pt">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">For the month
of September, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Commission
File Number: 001-39071</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 20pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ADC Therapeutics SA</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>(Exact
name of registrant as specified in its charter)</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>Biop&ocirc;le</B></FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>Route
de la Corniche 3B</B></FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>1066 Epalinges</B></FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>Switzerland</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>(Address
of principal executive office)</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">Indicate
by check mark whether the registrant files or will file annual reports under cover of Form&nbsp;20-F or Form 40-F:</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 29%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">Form 20-F</FONT></TD>
    <TD STYLE="width: 14%"><P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><FONT STYLE="font-size: 10pt">&#9746;</FONT></P></TD>
    <TD STYLE="width: 15%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 28%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">Form 40-F</FONT></TD>
    <TD STYLE="width: 14%"><FONT STYLE="font-size: 10pt"><!-- Field: Rule-Page --></FONT><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 0.5pt solid"><FONT STYLE="font-size: 10pt"></FONT></DIV></DIV><!-- Field: /Rule-Page --></TD></TR>
</TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Indicate by check mark if the
registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Indicate by check mark if the
registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 3.5pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="2" CELLPADDING="2" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>ADC Therapeutics SA</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Date: September 21, 2020</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 7%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 42%; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Dominique Graz</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Dominique Graz</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">General Counsel</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>EXHIBIT
INDEX</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="2" CELLPADDING="2" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%"><FONT STYLE="font-size: 10pt"><B>Exhibit No.</B></FONT></TD>
    <TD STYLE="width: 85%"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Press release dated September 21, 2020</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1
<SEQUENCE>2
<FILENAME>dp137015_ex9901.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;<IMG SRC="image_001.jpg" ALT=""></FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; background-color: white"><B>ADC
Therapeutics&nbsp;Submits Biologics License Application to the U.S. Food and Drug Administration for Loncastuximab Tesirine for
Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma</B></FONT></P>

<P STYLE="font: 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; background-color: white"><I>Submission
based on efficacy and safety data from LOTIS 2 clinical trial </I></FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Lausanne, Switzerland, September
21, 2020</B> &ndash; ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering
the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological
malignancies and solid tumors, today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug
Administration (FDA) for loncastuximab tesirine (Lonca) for the treatment of patients with relapsed or refractory diffuse large
B-cell lymphoma (DLBCL).</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&ldquo;The completion of our first
BLA submission to the FDA is a significant milestone for ADC Therapeutics and takes us one step further in our evolution toward
becoming a commercial-stage organization,&rdquo; said Chris Martin, Chief Executive Officer of ADC Therapeutics. &ldquo;We are
grateful to the trial participants and investigators and to all our employees for their commitment to this clinical program, and
we look forward to working with the FDA to bring Lonca to patients as quickly as possible.&rdquo;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">The BLA submission is based on
data from LOTIS 2, the pivotal Phase 2 multi-center, open-label, single-arm clinical trial evaluating the efficacy and safety
of Lonca in patients with relapsed or refractory DLBCL following &ge;2 lines of prior systemic therapy. In June 2020, the company
presented maturing data from LOTIS 2 at the virtual 25<SUP>th</SUP> Congress of the European Hematology Association. As of the
April 6, 2020 data cut-off date, 145 patients were enrolled in the trial and patients had received a median of 3 prior lines of
therapy. Lonca demonstrated an overall response rate of 48.3% (70/145 patients) and a complete response rate of 24.1% (35/145
patients). The tolerability profile was generally manageable, with the most common grade &ge;3 treatment-emergent adverse events
in &ge;10% of patients being: neutropenia (25.5%) with low incidence of febrile neutropenia (3.4%), thrombocytopenia (17.9%),
GGT increased (16.6%) and anaemia (10.3%).</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&ldquo;A critical unmet need remains
for heavily pretreated patients with relapsed or refractory DLBCL, including those with a poor prognosis, those who never responded
to prior therapy and those who received prior stem cell transplant,&rdquo; said Jay Feingold, MD, PhD, Senior Vice President and
Chief Medical Officer of ADC Therapeutics. &ldquo;Based on the anti-tumor activity, durability and generally manageable tolerability
Lonca has demonstrated in LOTIS 2, we believe Lonca has the potential to fill this need.&rdquo;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">The company has also initiated
LOTIS 5, a Phase 3 confirmatory clinical trial of Lonca in combination with rituximab, which is intended to support a supplemental
BLA for Lonca to be used as a second-line therapy for the treatment of relapsed or refractory DLBCL.</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>About Loncastuximab Tesirine
(Lonca)</B></FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Loncastuximab tesirine (Lonca,
formerly ADCT-402) is an antibody drug conjugate (ADC) composed of a humanized monoclonal antibody directed against human CD19
and conjugated through a linker to a pyrrolobenzodiazepine (PBD) dimer cytotoxin. Once bound to a CD19-expressing cell, Lonca
is</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">designed to be internalized by the cell, following which the warhead is released. The warhead is designed to bind irreversibly
to DNA to create highly potent interstrand cross-links that block DNA strand separation, thus disrupting essential DNA metabolic
processes such as replication and ultimately resulting in cell death. CD19 is a clinically validated target for the treatment
of B-cell malignancies.</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Lonca is being evaluated in LOTIS
2, a pivotal Phase 2 clinical trial in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), LOTIS 3, a
Phase 1/2 trial in combination with ibrutinib in patients with relapsed or refractory DLBCL or mantle cell lymphoma (MCL), and
LOTIS 5, a Phase 3 confirmatory clinical trial in combination with rituximab in patients with relapsed or refractory DLBCL.</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>About ADC Therapeutics</B></FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt">ADC Therapeutics
SA (NYSE:ADCT) is a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization
of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors. The
Company develops ADCs by applying its decades of experience in this field and using next-generation pyrrolobenzodiazepine (PBD)
technology to which ADC Therapeutics has proprietary rights for its targets. Strategic target selection for PBD-based ADCs and
substantial investment in early clinical development have enabled ADC Therapeutics to build a deep clinical and research pipeline
of therapies for the treatment of hematological and solid tumor cancers. The Company has multiple PBD-based ADCs in ongoing clinical
trials, ranging from first in human to pivotal Phase 2 clinical trials, in the USA and Europe, and numerous preclinical ADCs in
development.</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt">Loncastuximab
tesirine (Lonca, formerly ADCT-402), the Company&rsquo;s lead product candidate, has been evaluated in a 145-patient pivotal Phase
2 clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) that showed a 48.3% overall
response rate (ORR), which exceeded the target primary endpoint. Camidanlumab tesirine (Cami, formerly ADCT-301), the Company&rsquo;s
second lead product candidate, is being evaluated in a 100-patient pivotal Phase 2 clinical trial for the treatment of relapsed
or refractory Hodgkin lymphoma (HL) after having shown an 86.5% ORR in HL patients in a Phase 1 clinical trial. The Company is
also evaluating Cami as a novel immuno-oncology approach for the treatment of various advanced solid tumors.</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt">ADC Therapeutics
is based in Lausanne (Biop&ocirc;le), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. For
more information, please visit <FONT STYLE="color: Blue"><U>https://adctherapeutics.com/</U></FONT> and follow the Company on&nbsp;<FONT STYLE="color: Blue"><U>Twitter</U></FONT>&nbsp;and<U>&nbsp;<FONT STYLE="color: Blue">LinkedIn</FONT></U>.</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt"><B>Forward-Looking
Statements</B></FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">This press release contains statements
that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release,
including statements regarding our future results of operations and financial position, business strategy, product candidates,
research pipeline, ongoing and planned preclinical studies and clinical trials, regulatory submissions and approvals, research
and development costs, timing and likelihood of success, as well as plans and objectives of management for future operations are
forward-looking statements. Forward-looking statements are based on our management&rsquo;s beliefs and assumptions and on information
currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially
from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings
with the U.S. Securities and Exchange Commission.&nbsp;No assurance can be given that such future results will be</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">achieved. Such
forward-looking statements contained in this document speak only as of the date of this press release.&nbsp;We expressly disclaim
any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change
in our expectations or any change in events, conditions, or circumstances on which such statements are based unless required to
do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking
statements.</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>CONTACTS:</B></FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Investors</B><BR>
Amanda Hamilton<BR>
ADC Therapeutics</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt; color: Blue"><U>amanda.hamilton@adctherapeutics.com</U></FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Tel.: +1 917-288-7023</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>EU Media</B><BR>
Alexandre M&uuml;ller<BR>
Dynamics Group<BR>
<FONT STYLE="color: Blue"><U>amu@dynamicsgroup.ch</U></FONT><BR>
Tel: +41 (0) 43 268 3231</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>USA Media </B><BR>
Annie Starr<BR>
6 Degrees<BR>
<FONT STYLE="color: Blue"><U>astarr@6degreespr.com</U></FONT><BR>
Tel.: +1 973-415-8838</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !G )\# 2(  A$! Q$!_\0
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M/^$(\+_] *Q_[]"M349[FVM7G@6)A&C.PD)Y &>,5#]NG@^R_:_(43OMW*Q
M4;2W?Z4O;N+Y;M?UZE+#\ZYK)_G^0S_A&]&_Z!MO_P!\TY/#^D1G*Z=;@_[@
M-)<ZL(VNA#Y<@A@$H8-D9)(P<?2E-[<QV]Q-(]I((HF<+$Q)R!W]J'BGMS/^
MOF2L#'?D7W+_ "+T4$,"[88DC'HB@5)6='>727%O'<+ PG)4>2QRO!.2#VXI
M\>H[]3>U\O$?*K)G[S@ L/R/Z&I]K%[FGL9+8O45D/J=VL-S<^7;^1 [J5+$
M.0IQQVS3VO[E[NXBB:TC6)@H\YB&.5!_K4^VB5["?]?UYEVYL[:]C\NZMXIT
M_NR(&'ZUBS>!O#<[;FTN-3_L,R_H#6Q;W+37-S"RJ/)*C(/7*@U2EU"\^Q1W
M44<&QF"%7)SDOM[5HL0X*\6_D8RPD:KM**?K;J4X? OAN!MRZ7&Q_P!MV;]"
M:W+:SMK*+RK6WBAC_NQH%'Z56:]DMI EV(QB%YG:/. %(]?K0EQ?_NY9+:/R
MG(RB,2Z ]SV.._\ 6B6(<M)-L(82-/6$4ON+]%9@U"XEFE\E(66*0HT);$I
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+*+;0I5'))/H?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
